Background:

Patients on long-term insulin therapy frequently develop a condition called lipohypertrophy (LH), which involves the accumulation of abnormal fatty tissue at insulin injection sites. This condition is caused by repeated injections in the same area and can lead to inconsistent insulin absorption, unpredictable blood sugar levels, and increased risks of hypoglycemia and hyperglycemia. While standard care often includes verbal instructions on site rotation, many patients continue to struggle with technique and develop these complications.

Study Purpose:

This study aims to evaluate the effectiveness of a novel "Insulin Injection Sites Map" (provided in either digital or physical format) compared to standard verbal care. The study seeks to determine if this structured, visual mapping tool helps patients better manage their injection rotation, reduces the occurrence and severity of lipohypertrophy, and ultimately improves glycemic control (as measured by HbA1c and fasting blood glucose).

Study Design:

This is a prospective, randomized controlled trial (RCT) conducted at the outpatient medical clinic of Matrouh General Hospital. The study includes adult participants (aged 18 and older) diagnosed with Type 1 or Type 2 diabetes who have been using insulin therapy for at least six months.

Participants are divided into two groups:

Intervention Group: Patients who receive the novel structured insulin injection sites map and instructions on systematic rotation.

Control Group: Patients who receive routine care, consisting of standard verbal instructions on site rotation without visual mapping aids.

Outcome Measures:

Over a six-month follow-up period, the study monitors and compares both groups on the following key metrics:

Incidence and Severity of Lipohypertrophy: Evaluated through physical inspection and palpation of injection sites for lumps, firmness, or tenderness.

Adherence to Rotation Protocols: Measured using patient logs and site rotation scores to determine if participants are following the recommended rotation sequence.

Glycemic Control: Tracked through clinical monitoring of HbA1c percentages and fasting blood glucose levels to assess the impact of better injection technique on overall diabetes management.

Inclusion Criteria:

• Adults aged 18 years and older.
• Diagnosed with Type 1 or Type 2 diabetes mellitus.
• Currently receiving insulin therapy for a minimum of six months.
• Capable of self-injecting insulin or receiving assistance with injections at least once daily.
• Able and willing to provide informed consent to participate in the study.
• Able to understand and follow the study protocols.

Exclusion Criteria:

• Presence of mental illnesses or severe cognitive impairment that may affect participation.
• Individuals with skin disorders at injection sites (e.g., severe eczema, psoriasis, or infections) that could interfere with the evaluation of lipohypertrophy.
• Women who are pregnant or lactating.
• Participation in another interventional clinical trial within the past three months.

This study is an open-label randomized controlled trial. No masking is applied to participants, care providers, or investigators due to the nature of the intervention. Participants and care providers are aware of group allocation. Participants in the intervention group receive an evidence-based insulin injection site mapping tool, while participants in the control group receive standard verbal instructions on insulin injection technique. Outcome assessment is intended to be conducted independently to minimize measurement bias; however, no additional formal blinding procedures are implemented. The open-label design is appropriate given the educational and behavioral nature of the intervention, which requires active participant engagement and provider instruction to improve adherence to correct insulin injection practices and reduce the risk of lipohypertrophy.